Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update - sprookjes - yvandenbroek - TriplyDB

Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update

Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update

http://www.wikidata.org/entity/Q28299995

about

Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options Acetylsalicylic acid (aspirin) for schizophrenia Early interventions for prodromal stage of psychosis Cytokines in Schizophrenia: Hope or Hype?Microglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric Disorders The role of inflammation in schizophrenia The neuroimmunology of schizophrenia The cytokine model of schizophrenia: emerging therapeutic strategies In vivo imaging of neuroinflammation in schizophrenia Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies.Transcriptome sequencing study implicates immune-related genes differentially expressed in schizophrenia: new data and a meta-analysis.Immunological aspects of the treatment of depression and schizophrenia.Recent advances in understanding schizophrenia A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.Paliperidone prevents brain toll-like receptor 4 pathway activation and neuroinflammation in rat models of acute and chronic restraint stress.The use of clinical and biological characteristics to predict outcome following First Episode Psychosis.Brain in flames - animal models of psychosis: utility and limitations Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis.The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis Simvastatin augmentation for recent-onset psychotic disorder: A study protocol.Is there a role for immune-to-brain communication in schizophrenia?Microglial activation and progressive brain changes in schizophrenia.Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia.Can anti-inflammatory medications improve symptoms and reduce mortality in schizophrenia?Higher Plasma S100B Concentrations in Schizophrenia Patients, and Dependently Associated with Inflammatory Markers.Genome-Wide Association Studies Suggest Limited Immune Gene Enrichment in Schizophrenia Compared to 5 Autoimmune Diseases.Metabolic Abnormalities in the Hippocampus of Patients with Schizophrenia: A 3D Multivoxel MR Spectroscopic Imaging Study at 3T.Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study.Ethical Implications of the Mild Encephalitis Hypothesis of Schizophrenia.Vitamin-D Deficiency As a Potential Environmental Risk Factor in Multiple Sclerosis, Schizophrenia, and Autism.Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective.Targeting of NMDA receptors in new treatments for schizophrenia.The neurobiology and treatment of first-episode schizophrenia.Emerging drugs for schizophrenia: an update.Maternal immune activation and abnormal brain development across CNS disorders.Role of T helper lymphokines in the immune-inflammatory pathophysiology of schizophrenia: Systematic review and meta-analysis.

P2860

Q22241447-FFCE6EB6-54BC-4482-B214-EEAABC0BA7D4 Q24186077-3851915B-FC89-41CD-8E50-6D366F7A8635 Q26471731-F53728F5-CB4E-424A-AD74-48A746D69B48 Q26750430-50182AA1-DD91-417A-8ED2-9AC0C3EACC79 Q26767489-DE931A65-2147-4197-9025-D7C18E56F50C Q26779719-0081C6F5-FBEB-46EA-92B3-647F07B20E77 Q26859392-73FC880A-FF4F-4939-82F8-8AD12D4A9762 Q26865996-30E31C75-441D-4372-AD6E-2EB14FE7178B Q30966978-537A967D-7097-45E0-9391-37F3689483A0 Q33601896-514310A3-9371-4CCA-BDDA-50F0490C2811 Q33635637-7E5EB7EB-BE59-4E87-A743-E75E56399F64 Q33721031-EFADAF6D-42A5-4BF6-8BFD-6A4A55DE456A Q33942094-15617699-050B-4F41-B986-48B34BFD47CA Q34405264-656FC136-4C70-4D72-9352-8E2D3965542C Q35179057-3FFB6330-3D09-4476-AC04-3E8C49AA5633 Q35457414-2C771CCA-021E-431C-9BB2-B13CA1E883BC Q35683865-73A79396-824F-40F8-94FD-77AF66191CC4 Q35950801-3B461917-4C15-4046-B581-B1B84BF5C0F9 Q35955612-A7C6E884-BF18-4C55-A303-D46B9EB16833 Q36324327-DEDB3679-E621-4B5F-80B5-F4847F3246A0 Q36351021-438A4379-BBE3-46D1-B0F7-8B918337C54A Q36546971-ACA8F06F-6FD0-4353-9559-60C4F3C1F415 Q36579965-1D49B21B-808A-4787-8489-AC863ED3A0BC Q36580009-978FE964-8A71-438F-A6C1-F72BEDC22DC8 Q36594940-7721CE54-40D5-4FBB-8DF8-013A854427ED Q36858447-4E545CF4-5725-47D5-9664-EDEC2D834006 Q36965956-91968957-8DC7-4CDE-B769-BB39CB8AFD55 Q36986134-AFC76090-A68E-44BB-BA59-560834E373F8 Q37183966-9E405CC3-B179-49F2-92C5-20F96DB11139 Q37510500-4F6819ED-88C5-4CFD-9590-5B05D0CA871D Q37524068-7BC61D23-858B-45E6-9614-82E53566F23F Q37694507-BE0AE2EE-3A32-4F5A-853D-A2943753BE64 Q37721243-78BE8465-646D-4A5C-BA2C-0C2964105669 Q37721268-EC7D4987-9D74-46F5-8291-B094D7C3A7E8 Q38203063-A4ABCE12-CE11-4996-B2AD-4D55FE291E01 Q38223276-068217FB-213E-42F3-9680-E2D097A22B63 Q38232366-98FFF851-D91F-4A8A-9FFF-8CEA570BE0DC Q38252404-ED3F70D8-1F22-4A74-BF1C-270F5BE34808 Q38259759-A9E6A3EC-D61F-4951-ADAA-5635E2425A72 Q38296243-DF436014-EE19-44D2-ACBC-3EB447669FB9

P2860

Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update

http://www.wikidata.org/entity/Q28299995

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Efficacy of anti-inflammatory ...... with schizophrenia: an update

@ast

Efficacy of anti-inflammatory ...... with schizophrenia: an update

@en

Efficacy of anti-inflammatory ...... with schizophrenia: an update

@nl

type

label

Efficacy of anti-inflammatory ...... with schizophrenia: an update

@ast

Efficacy of anti-inflammatory ...... with schizophrenia: an update

@en

Efficacy of anti-inflammatory ...... with schizophrenia: an update

@nl

prefLabel

Efficacy of anti-inflammatory ...... with schizophrenia: an update

@ast

Efficacy of anti-inflammatory ...... with schizophrenia: an update

@en

Efficacy of anti-inflammatory ...... with schizophrenia: an update

@nl

P1433

Q28299995-64E4D400-1854-4420-B1F2-F15845D0ED39

P1476

Q28299995-5E2508A2-500B-4145-A6AB-43303D940106

P2093

Q28299995-7CE7073D-7500-4018-A8C7-0C38825C1223

Q28299995-8868F075-4B40-4255-A400-00C631C94205

Q28299995-FA92A46D-CD7D-49F4-8845-55D4057DCAEB

P2860

Q28299995-0C175A51-AEEC-4107-BE13-9BC5AC4F54B6

Q28299995-1081A04B-5749-4784-9B24-911D129504AC

Q28299995-16EFD0DC-8D0A-49AD-A755-54AAA6D2180E

Q28299995-1919C01B-00BE-4664-8986-7D397C9AD7DA

Q28299995-21B2395A-6D60-495C-B660-DDED89B345C9

Q28299995-242B9264-10D0-4DDA-8BC2-15857E5FB4D9

Q28299995-28D89FAC-DC56-4923-819F-FA7E515B9F04

Q28299995-2AB411F5-4C38-4FB8-92A1-2D67194D5E58

Q28299995-2FF6C0A9-DE86-44F1-B60D-151A9160ADD9

Q28299995-33F8D486-444B-4983-9595-79CC0921C7C4

P304

Q28299995-40BFC156-40A1-4A3D-BDED-5AF946DD3E91

P31

Q28299995-6657B8EE-4EDC-4D74-A4B0-A76D1629AC6A

Q28299995-90b452d7-9e09-4a98-b955-d668c44e2f97

P3181

Q28299995-DDC80989-1BCA-4741-8142-DB3CE1434EAE

P356

Q28299995-4A4DF43F-F0ED-4E7D-94FE-7AA2B1F97224

P407

Q28299995-68D38288-D31F-4A1D-9683-B8DDE1A80D52

P433

Q28299995-70E2F09F-7142-43A5-BEFE-F44FA9E5BA61

P478

Q28299995-A5EEC695-FFCF-49D1-8222-F50DB922BC8C

P50

Q28299995-614F2943-9D95-4373-9D20-2DC4A9321E56

Q28299995-7DFA5295-9AAD-499A-9F97-454151A6BD61

Q28299995-CFD60B56-E793-4FEA-8B21-96926415D349

P577

Q28299995-DBB10A48-C7AA-4C9D-90FB-C464D61E3180

P5875

Q28299995-80BCA448-58AD-42D9-8AEB-C1F40F91BC78

P698

Q28299995-5FE89658-EDFD-4695-8910-C305D8A105C4

P921

Q28299995-5E2152C7-6C6A-4976-95E5-20AFD6662F3E

Q28299995-9DF3A3C9-5C3A-4DD8-B5FC-FC4FECA0D374

Q28299995-E59F2566-DAB4-46F9-8962-B7D26BD75C70

P932

Q28299995-3EE2E371-BC1B-421E-AEA4-8CEEDC190829

P3181

P356

P1433

Schizophrenia Bulletin

P1476

Efficacy of anti-inflammatory ...... with schizophrenia: an update

@en

P2093

Lot D de Witte

http://www.w3.org/2001/XMLSchema#string

Marieke J H Begemann

http://www.w3.org/2001/XMLSchema#string

Roos van Westrhenen

http://www.w3.org/2001/XMLSchema#string

P2860

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action

Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Measuring inconsistency in meta-analyses

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

Putative neuroprotective agents in neuropsychiatric disorders

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial

Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

P304

181-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

902700

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/SCHBUL/SBT139

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257535784

http://www.w3.org/2001/XMLSchema#string

P698

24106335

http://www.w3.org/2001/XMLSchema#string

P921

P932

3885306

http://www.w3.org/2001/XMLSchema#string